Albumin exfoliated titanium disulfide nanosheet: a multifunctional nanoplatform for synergistic photothermal/radiation colon cancer therapy.

PURPOSE: TiS2-HSA-FA, a nanoagent based on titanium disulfide (TiS2), human serum albumin (HSA), and folic acid (FA), was synthesized for potential use in synergistic photothermal/radiation therapy for colon cancer.
METHODS: TiS2 nanosheets were synthesized through a HSA-assisted exfoliation method and then modified with PEGylated FA. The morphology, size, zeta potential, stability, cellular uptake, cytotoxicity, biodistribution, and in vitro and in vivo biocompatibility of the nanoparticles as well as their suitability for synergistic photothermal/radiation colon cancer therapy were investigated.
RESULTS: The as-synthesized TiS2-HSA-FA nanoparticles showed excellent physiological stability, as well as high absorption values in the near-infrared (NIR) and X-ray regions, giving them superb activity as a photothermal and radiation sensitizer. In vitro and in vivo experiments indicated that TiS2-HSA-FA showed high tumor targeting selectivity, blood circulation time, biocompatibility, and suitability for synergistic tumor photothermal radiotherapy.
CONCLUSION: A multifunctional nanoplatform based on TiS2 was developed and found to be potentially suitable for synergistic photothermal/radiation therapy for colon cancer.

Introduction

Although anti-tumor therapeutics have greatly improved in recent decades, malignant tumors are still a major threat to human beings’ health worldwide.1,2 One of the most commonly used treatment strategies is radiotherapy (RT), in which tumors are exposed to ionizing radiation such as X-rays in an attempt to produce necrosis of tumor tissue through DNA damage and generation of reactive oxygen species.3–5 However, in practice, RT has several drawbacks. One is that it can harm normal tissue and thereby induce acute side effects such as nausea and vomiting, hair loss, etc.6,7 Another is that considerable dose must be used to ensure that all tumor cells are killed, and yet X-ray irradiation has no tumor specificity. This necessitates excessively large radiation doses, inevitably causing injury to healthy tissues. To overcome these drawbacks, a series of radio-sensitizers such as the two-dimensional (2D) layered transition metal dichalcogenides (TMDs) (MoS2, WS2, MoSe2, and ReS2) and other inorganic materials have been prepared.8–13 Most TMDs were reported to contain high-Z elements that can act as radio-sensitizers to promote the cancer RT effect by absorbing X-rays and concentrating the radiation dose within tumors.14–16 For example, Shen and co-authors have prepared uniform ultrathin rhenium disulfide nanosheets for photothermal RT.16 However, the hypoxic environment inside tumors is still considered a major challenge for successful use of radio-sensitizers in RT.17,18

Photothermal therapy (PTT) has attracted substantial interest of late, as an alternative tumor treatment strategy.19,20 It is minimally invasive, and its high specificity means minimal side effects in normal tissues. PTT relies on photothermal agents to convert absorbed light energy into heat to kill tumor cells.21–23 Recently, various nanomaterials such as organic small molecules,24,25 TMDs-based nanocomposites,19,26 protein-based nanoparticles,27,28 etc. have been developed as PTT nanoagents.29–31 Among these, TMD-based nanoagents have demonstrated great potential for PTT because of their strong absorbance in the near IR (NIR) region and their large specific surface area which facilitates their functional modification. In addition, under NIR laser irradiation, TMD-based nanoagents can increase intratumor blood circulation, thereby facilitating oxygen availability inside the tumor, which could facilitate the RT effect.16,32,33 It is, therefore, thought that some type of TMD nanomaterial could be found which could act as an “all in one” nanoagent, perfectly combining RT and PTT for optimal therapeutic effect.

In this work, we prepared a new multifunctional nanoagent for combined PTT and RT, using tumor-targeted molecule FA and PEG modification of albumin exfoliated TiS2 nanosheets (TiS2-HSA-FA). TiS2, as a new member of the TMD family, has been reported to have a high NIR absorbance which makes it an attractive candidate for PTT.34–36 Given its potential as a dual-modality therapy nanoagent, its efficacy as a radio-sensitizer is investigated here for the first time. The advantages of the developed nanoplatform TiS2-HSA-FA include: 1) improved stability and biocompatibility of TiS2 due to the PEG and HSA modification; 2) great radio-sensitivity; 3) high photothermal effect under NIR laser irradiation; and 4) remarkable tumor cell targeting effect after sequential conjugation with FA. The in vitro and in vivo results demonstrated that TiS2-HSA-FA are a highly effective nanoagent for synergistic photothermal/radiation therapy, which may ultimately prove to be suitable for clinical use.

Methods

Materials

Titanium disulfide (TiS2, Crystal, 99.995%) and Cell counting kit-8 (CCK-8) were purchased from Sigma-Aldrich (St. Louis, Mo, USA). FA-PEG5,000-NHS and CH3-PEG5,000-NHS were obtained from Xi ‘an Kaixin Biotech. Co. Ltd (China). Human serum albumin (HSA) and Fluorescein isothiocyanate (FITC) were obtained from Aladdin (Shanghai, China). Calcein-AM (CA)-propidium iodide (PI) stain were purchased from Sigma-Aldrich (St. Louis, Mo, USA).

Preparation and characterizations of Tis2-HSA-FA

In detail, 20 mg bulk TiS2 was added into 10 mL distilled water, following 2 hrs ultrasonication (2s on and 3s off) in a sonicator Omni Sonic Ruptor 4000 (Omni International, Kennesaw, GA, USA). After that, 10 mg HSA was added to the mixture and sonicated at the same condition for further 6 hrs. After centrifugation at 7000 rpm for 18 mins, the supernatant was collected and centrifuged at 10,000 rpm for 20 mins, resulting in TiS2 nanosheets solution. Next, 10 mL TiS2 nanosheets (1 mg/mL) is mixed with FA-PEG5,000-NHS (10 mg) and stirred for 2 hrs to be TiS2-HSA-FA. As a contrast, FA-PEG5,000-NHS was replaced by CH3-PEG5,000-NHS to form TiS2-HSA. Lastly, the resulted mixture was purified by dialysis in distilled water over 24 hrs to obtain TiS2-HSA and TiS2-HSA-FA. The morphology, size, zeta potential, XRD, and UV-VIS spectra of the resulted products were detected on atomic force microscopy (AFM, multimode, digital instruments, Veeco Company, USA), FEI transmission electron microscope (Eindhoven, The Netherlands), ZetaSizer Nano ZS (Malvern Instruments Ltd., UK), X-ray diffractometer (D8 ADVANCE, Bruker, Germany), UV-VIS spectrophotometry (UV-Vis 1800, Shimadzu, Kyoto, Japan), Fourier transform infrared spectroscopy (FT-IR, Bruker Optics GmbH, Ettlingen, Germany), respectively.

Cell culture

CT26 cells (mice colon cancer cell line) were obtained from Type Culture Collection of Chinese Academy of Science (Shanghai, China). CT26 cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 1% penicillin and streptomycin in an atmosphere of 5% CO2 at 37°C.

Cellular uptake and in vitro biocompatibility

According to previous literatures, a classic small molecule dye, FITC, was applied to label the nanoparticles by simple physical absorption. After 24 hrs incubating, CT26 cells were cultured with free FITC, TiS2-HSA, TiS2-HSA-FA + FA, and TiS2-HSA-FA for 4 hrs, respectively. And then, the treated cells were successively washed by phosphate buffer saline (PBS) for three time slightly and fixed by glutaraldehyde, stained with DAPI for 10 mins. A commercial confocal laser scanning microscope was used to observe the fluorescence signals inside cells. Moreover, the treated cells were homogenized, and treated with 1 mL aqua regia solution for 5 hrs. An inductively coupled plasma−atomic emission spectrometry (ICP-AES, Hitachi P4010, Japan) was applied to detect the Ti content in the cells.

The in vitro biocompatibility of TiS2-HSA and TiS2-HSA-FA on cells was evaluated by a standard CCK-8 assay. In detail, CT26 cells (1×105 cells/mL, 0.5 mL) were cultured in 96-well plate for 24 hrs and then, the cells were treated with different concentration of TiS2-HSA and TiS2-HSA-FA. After 24 hrs incubation, the cell viability was detected by CCK-8 assay.

In vitro synergistic PTT/RT

CT26 cells were treated with different concentration of TiS2-HSA and TiS2-HSA-FA (0, 10, 30, 50, 100, 150 μg/mL) and were cultured in 37°C incubator for 5 hrs. After washing the nanoparticles outside the cells, they were irradiated with NIR irradiation (808 nm laser at a power density of 0.8 W/cm2 for 5 mins) or RT (5Gy), or their combination. And then, the treated cells were further cultured for 24 hrs. During the 5 mins NIR irradiation, a handheld thermal camera (Ti27, Fluke, USA) was used to record the temperature change of the cells. The cell death rate was calculated using a typical CCK-8 assay.

As above, the cells were treated with TiS2-HSA and TiS2-HSA-FA, following by irradiation with NIR irradiation and X-ray at the same condition. According to the previous literatures, the cells were further stained with calcein-AM/PI and γ-H2AX, respectively, to evaluate the cell death. The fluorescence signal of stained cells was observed by a confocal laser scanning microscope (LSM 510 NLO META, Zeiss, Germany).

Animal model

We have revised the ethics statement: All animal experiments were strictly complied with the guideline of Animal Protection and Care Committee of Sichuan University. All animal experimental procedures involved in this work were approved by the Ethics Committee of Sichuan University. For CT26 tumor xenograft models, 106 CT26 cells in 150 μL PBS were subcutaneously injected into the right back of mice. After 7–10 days of inoculation, the tumor size was detected by a caliper.

In vivo synergistic PTT/RT

To investigate the synergistic PTT/RT, tumor-bearing mice were randomly divided into 5 groups (n=5): group 1: control + NIR + RT; group 2: TiS2-HSA-FA + RT; group 3: TiS2-HSA-FA + NIR; group 4: TiS2-HAS + RT+NIR; and group 5: TiS2-HSA-FA + RT+NIR (with 6 mg/kg of TiS2). NIR irradiation used 808 nm wavelength laser with 0.8 W/cm2. RT applied 5 Gy X-ray for 5 mins. The temperature change of the tumor region when irradiated by NIR was recorded using an infrared thermal camera. Every three days treatment, the tumor size was recorded and the tumor volume was calculated according to the equation: V = length × width2/2. The relative tumor volume was calculated as V/V (V: current volume, V: initial tumor volume). After the whole treatment, the major organs of these mice were collected for hematoxylin and eosin (H&E) staining. In addition, the blood was collected and the index including white blood cell (WBC), red blood cells (RBC), hemoglobin (HGB), mean corpuscular hemoglobin (MCH), hematocrit (HCT), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), and platelet (PLT) were detected.

Statistical analysis

All data were presented as mean with standard deviation (SD). Statistical analysis was analyzed with OriginPro 2016 via Students’s t-test. The differences were considered significant for *P<0.05 and highly significant for **P<0.01.

Results and discussion

Preparation and characterization of TiS2-HSA-Fa

TiS2 nanosheets were first prepared by HSA-assisted ultrasonication, and their sheet structure was confirmed by AFM image (Figure S1). They were then modified by PEGylated FA to produce TiS2-HSA-FA. TEM imaging shows that TiS2-HSA-FA has a sheet-like structure with a lattice plane spacing of 0.24 nm (Figure 1A). As shown in Figure 1B, the sharp and narrow XRD peaks in TiS2-HSA-FA indicate good crystallinity of the prepared TiS2-HSA-FA, consistent with observations from HRTEM (Figure 1A, inset). In addition, both bulk TiS2 and TiS2-HSA-FA showed the same phase structure, demonstrating that the exfoliation process has no significant influence on the crystalline structure of the material.37 According to DLS analysis, the zeta potential and average diameter of TiS2-HSA-FA nanoparticles were approximately −31.2 mV and 135.3 nm, respectively (Figure 1C and D). After 15 days of storage in physiological solution, the size of the TiS2-HSA-FA nanoparticles displayed no notable changes (Figure 1E). This stability is likely due to the absorption of HSA onto the surface of the particles, and subsequent modification with PEG. The UV-Vis spectrum of TiS2-HSA-FA in Figure 1F shows high absorbance across all wavelengths from UV to NIR. The extinction coefficient of TiS2-HSA-FA at 808 nm was found to be 30.1 L/g cm. In addition, as shown in Figure S2, the more intense ~1650 cm−1 peak in TiS2-HSA-FA indicated the existence of the amido bond between TiS2-HSA and FA.

Figure 1

Preparation and characterization.

Notes: (A) TEM image of TiS2-HSA-FA. Inset was the high-resolution TEM image. (B) XRD pattern of bulk TiS2 and TiS2-HSA-FA. (C) The zeta potential distribution of TiS2-HSA-FA. (D) The size distribution of TiS2-HSA-FA. (E) The size change of TiS2-HSA-FA in physiological solution over 15 days. (F) The absorbance spectra of TiS2-HSA-FA.

Abbreviations: TiS2, titanium disulfide; HSA, human serum albumin; FA, folic acid; TEM, transmission electron microscopy; XRD, X-ray diffraction.

Photothermal effect of TiS2-HSA-FA

To test the photothermal properties of TiS2-HSA-FA, different concentrations (0, 50, 100, and 150 mg/mL) of the nanoparticles were irradiated by NIR laser (808 nm, 0.8 W/cm) for 5 mins. The results showed that laser irradiation produced significant concentration-dependent temperature increases in TiS2-HSA-FA (Figure 2A). The highest temperature that could be reached was 65.3°C. According to previous literatures,38–40 the photothermal conversion efficiency of TiS2-HSA-FA was calculated to be ~58.9%. The photothermal stability of TiS2-HSA-FA was also investigated (Figure 2B); TiS2-HSA-FA were clearly very stable throughout five cycles of NIR irradiation. In addition, the Hounsfield unit values of TiS2-HSA-FA, detected by computed tomography, were positively correlated with concentration (Figure 2C), demonstrating that TiS2-HSA-FA is a very effective radio-sensitizer.

Figure 2

The photothermal and radio-sensitization property.

Notes: (A) Temperature changes of TiS2-HSA-FA solution with various concentrations under 808 nm laser irradiation (0.8 W/cm2). (B) Temperature variations of TiS2-HSA-FA under 5 cycles of 808 nm laser irradiation (0.8 W/cm2). (C) The correlation between HU values and different concentrations of TiS2-HSA-FA. The inset is CT images.

Abbreviations: TiS2, titanium disulfide; HSA, human serum albumin; FA, folic acid; CT, computed tomography.

After labeling by FITC, the behavior of TiS2-HSA and TiS2-HSA-FA in cells was tracked by fluorescence microscopy. The fluorescence images showed that cells treated with TiS2-HSA-FA showed much more fluorescence signal in cytoplasm than those treated with TiS2-HSA-FA + FA, TiS2-HSA, and free FITC (Figure 3A). ICP-AES quantitative analysis confirmed these results (Figure 3B). This indicates that FA conjugation significantly accelerated endocytosis of TiS2-HSA-FA. In addition, the in vitro biocompatibility of the TiS2-HSA-FA was evaluated by standard CCK-8 assay. As shown in Figure 3C, no significant cytotoxicity of TiS2-HSA-FA was found even at high concentrations up to 0.8 mg/mL, indicating good in vitro biocompatibility for both TiS2-HSA and TiS2-HSA-FA.

Figure 3

Cell uptake and biocompatibility.

Notes: (A) Fluorescence images of CT26 cells incubated with free FITC and FITC labeled TiS2-HSA, TiS2-HSA-FA + FA blocking, and TiS2-HSA-FA. (B) Quantitative analysis of CT26 cells towards free FITC and FITC labeled TiS2-HSA, TiS2-HSA-FA + FA blocking, and TiS2-HSA-FA by ICP-AES. (C) Cell viability of CT26 cells after 24 hrs treatment with different concentrations of TiS2-HSA and TiS2-HSA-FA.

Abbreviations: TiS2, titanium disulfide; HSA, human serum albumin; FA, folic acid; ICP-AES, inductively coupled plasma-atomic emission spectrometry; FITC, fluorescein isothiocyanate; DAPI, 4ʹ,6-diamidino-2-phenylindole.

As shown in Figure 4A, CT26 cells treated with TiS2-HSA-FA showed 28.5°C of temperature increase after 5 mins of NIR laser irradiation (808 nm, 0.8 W/cm2), which was higher than that of either TiS2-HSA-treated or control-treated cells. Since the data from Figure 2C suggested that TiS2 has potential as a radio-sensitizer, the in vitro RT efficacy of TiS2-HSA-FA was tested: as seen in Figure 4B, cell viability decreased with increasing X-ray dose. TiS2-HSA-FA + RT exhibited greater inhibition of cell viability than either TiS2-HSA-treated or control-treated cells. This is likely because TiS2-HSA-FA is more effectively endocytosed, and thus can absorb the energy of X-ray radiation more effectively inside tumor cells and channel it into the formation of secondary Auger electrons to damage DNA.41–43

Figure 4

In vitro photothermal radiotherapy.

Notes: (A) Temperature change curve of control, TiS2-HSA and TiS2-HSA-FA under 5 mins NIR irradiation (808 nm, 0.8 W/cm2). (B) Cell viability of CT26 cells treated by TiS2-HSA and TiS2-HSA-FA and were irradiated by different dose of X-ray. (C) Cell viability of CT26 cells treated by TiS2-HSA and TiS2-HSA-FA and irradiated by NIR laser or X-ray. (D) Live−dead staining images of CT26 cells treated with PBS, PBS + NIR, TiS2-HSA-FA, TiS2-HSA-FA + NIR. (E) γ-H2AX staining images of CT26 cells treated with PBS + RT, PBS + NIR, TiS2-HSA-FA, TiS2-HSA-FA + NIR, TiS2-HSA-FA + RT, and TiS2-HSA-FA + NIR+ RT, respectively.

Abbreviations: TiS2, titanium disulfide; HSA, human serum albumin; FA, folic acid; RT, radiation therapy; NIR, near infrared; PBS, phosphate buffer saline.

The effect of combined PTT/RT treatment was then investigated. Cells were treated with control + NIR + RT, TiS2-HSA-FA + RT, TiS2-HSA-FA + NIR, TiS2-HAS + NIR + RT, or TiS2-HSA-FA + NIR + RT. As shown from the standard CCK-8 assay, under NIR and RT treatment, TiS2-HSA-FA displayed the highest cell inhibition rate (93.4%) of all the groups (Figure 4C).

Calcein-AM/PI staining and γ-H2AX immunofluorescence were further used to evaluate the combined effect of PTT and RT. The RT- and PTT-treated cells were stained by calcein-AM/PI. As shown in Figure 4D, almost all the cells were killed in the TiS2-HSA-FA + NIR + RT group, while few were killed in the PBS, PBS + NIR, and TiS2-HSA-FA groups. Figure 4E shows the results of γ-H2AX immunofluorescence. In PBS + RT, PBS + NIR, TiS2-HSA-FA, and TiS2-HSA-FA + NIR-treated groups, negligible γ-H2AX immunofluorescence was seen. By contrast, the TiS2-HSA-FA + RT and TiS2-HSA-FA + NIR + RT-treated groups exhibited strong γ-H2AX immunofluorescence signals, suggesting that TiS2-HSA-FA can enhance the radio-sensitivity of cells and produce more DNA damage.

In vivo biodistribution and blood circulation

Titanium content of the major organs post-injection of TiS2-HSA and TiS2-HSA-FA were evaluated. The majority of the two nanoparticles were distributed in liver and kidney. Much more TiS2-HSA-FA was collected in tumor tissue than TiS2-HSA (Figure 5A). The concentration of TiS2-HSA-FA in tumor tissue peaked at 24 hrs post-injection (Figure 5B). The accumulation of TiS2-HSA-FA in tumor was likely due to the FA modification, which is known to facilitate tumor targeting.44,45 As shown in Figure 5C, after intravenous injection, blood distribution half-life (t1/2α) and blood terminal elimination half-life (t1/2β) of the TiS2-HSA-FA were 1.21±0.11 hrs and 17.52±0.62 hrs, respectively. It has been reported that PEG and HSA modifications can prolong blood circulation and reduce macrophage clearance of nanoparticles from the reticuloendothelial system.46,47

Figure 5

In vivo biodistribution and blood circulation.

Notes: (A) Ti concentration in tumor and major organs (heart, liver, spleen, lung, and kidney) of TiS2-HSA- and TiS2-HSA-FA-treated mice. (B) Ti concentration in tumor region of TiS2-HSA- and TiS2-HSA-FA-treated mice at different time points. (C) Ti concentration in blood at different time points after injection of TiS2-HSA-FA.

Abbreviations: TiS2, titanium disulfide; HSA, human serum albumin; FA, folic acid.

For in vivo synergistic PTT/RT, NIR (5 mins, 808 nm, 0.8 W/cm2) and X-ray (5 mins, 5Gy) irradiation were applied 24 hrs after intravenous injection. The temperature of the tumor region was recorded by a thermal imager. Figure 6A and B showed a roughly 25°C increase in TiS2-HSA-FA + NIR-treated mice, compared to those treated with control or TiS2-HAS + NIR. The weight of the mice increased normally over the duration of the 21-day treatment (Figure 7A). The best tumor growth inhibition effect was observed with combined PTT/RT in group 5 (TiS2-HSA-FA + NIR+RT). The results demonstrated that PTT/RT delivered by TiS2-HSA-FA have an obviously synergistic therapeutic outcome compared to PTT or RT alone (Figure 7B).

Figure 6

In vivo photothermal performance.

Notes: (A) In vivo thermal images of mice after intravenous injection of saline, TiS2-HSA and TiS2-HSA-FA under 5 mins NIR irradiation (808 nm, 0.8 W/cm2). (B) The corresponding temperature change curves of tumor regions in mice.

Abbreviations: TiS2, titanium disulfide; HSA, human serum albumin; FA, folic acid; RT, radiation therapy; NIR, near infrared.

Figure 7

In vivo synergistic photothermal radiotherapy.

Notes: The change of (A) body weight and (B) relative tumor volume of CT26-bearing mice in different groups, including control (saline) + NIR+RT, TiS2-HSA-FA + RT, TiS2-HSA-FA + NIR, TiS2-HAS + NIR + RT, and TiS2-HSA-FA + NIR + RT. **P<0.01, compared to other groups.

Abbreviations: TiS2, titanium disulfide; HSA, human serum albumin; FA, folic acid; RT, radiation therapy; NIR, near infrared.

After the treatment, the heart, liver, spleen, lung, kidney, and whole blood were collected for HE section staining and complete blood panel assays to evaluate the biocompatibility of the nanoparticles. As seen in Figure 8A and B, no obvious differences were observed between the TiS2-HSA-FA group and the control group. This indicates that TiS2-HSA-FA has good in vivo biocompatibility.

Figure 8

In vivo biocompatibility.

Notes: (A) HE-stained images of heart, liver, spleen, lung, and kidney collected from mice after 21 days treatment (scale bar =100 μm). (B) Blood biochemistry of mice after 21 days treatment.

Abbreviations: TiS2, titanium disulfide; HSA, human serum albumin; FA, folic acid; HE, hematoxylin and eosin; WBC, white blood cell; RBC, red blood cells; HGB, hemoglobin; MCH, mean corpuscular hemoglobin; HCT, hematocrit; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; PLT, platelet.

Conclusion

In summary, we have prepared a biocompatible PTT/RT nanoplatform TiS2-HSA-FA by using simple ultrasonication to create albumin exfoliated TiS2 nanosheets that were then modified with PEG and FA. The TiS2-HSA-FA nanoparticles showed strong NIR light absorbance, good stability, and remarkable efficacy as a radio-sensitizer. In vitro and in vivo characterization showed TiS2-HSA-FA to have a high specificity for targeting tumors, likely due to its modification with FA. The nanoparticles also produced a remarkable, synergistic, cytotoxic effect under PTT/RT irradiation, and showed great biocompatibility in vitro and in vivo. This multifunctional nanoplatform shows great promise for future use as a new tumor therapeutic agent.

Supplementary materials

(A) The AFM image and (B) height analysis of TiS2 nanosheets.

Abbreviations: AFM, atomic force microscopy; TiS2, titanium disulfide.

The FT-IR spectrum of TiS2-HSA and TiS2-HSA-FA.